Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chronic Pain | 4 | 2024 | 238 | 1.560 |
Why?
|
| Pain | 11 | 2013 | 1658 | 0.820 |
Why?
|
| Telemedicine | 2 | 2024 | 471 | 0.630 |
Why?
|
| Analgesics | 3 | 2019 | 390 | 0.620 |
Why?
|
| Pain Management | 7 | 2021 | 668 | 0.520 |
Why?
|
| Pandemics | 2 | 2024 | 1559 | 0.520 |
Why?
|
| Analgesics, Opioid | 7 | 2019 | 1371 | 0.430 |
Why?
|
| Peripheral Nervous System Diseases | 4 | 2018 | 393 | 0.390 |
Why?
|
| Chondrosarcoma | 1 | 2013 | 216 | 0.380 |
Why?
|
| Practice Management | 1 | 2008 | 12 | 0.330 |
Why?
|
| Polypharmacy | 1 | 2008 | 57 | 0.310 |
Why?
|
| Hydrocodone | 2 | 2019 | 55 | 0.310 |
Why?
|
| Spinal Neoplasms | 1 | 2013 | 631 | 0.310 |
Why?
|
| Neurofeedback | 2 | 2018 | 19 | 0.310 |
Why?
|
| Neoplasms | 15 | 2021 | 15193 | 0.290 |
Why?
|
| Osteosarcoma | 1 | 2013 | 929 | 0.270 |
Why?
|
| Substance Abuse Detection | 2 | 2018 | 64 | 0.260 |
Why?
|
| Cancer Pain | 2 | 2021 | 312 | 0.260 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2007 | 500 | 0.230 |
Why?
|
| Opioid-Related Disorders | 3 | 2013 | 394 | 0.230 |
Why?
|
| Fentanyl | 2 | 2019 | 148 | 0.210 |
Why?
|
| Controlled Substances | 2 | 2019 | 15 | 0.190 |
Why?
|
| Sacroiliac Joint | 1 | 2019 | 19 | 0.180 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 1303 | 0.170 |
Why?
|
| Acute Pain | 1 | 2019 | 42 | 0.170 |
Why?
|
| Arthralgia | 1 | 2019 | 89 | 0.160 |
Why?
|
| Low Back Pain | 1 | 2019 | 83 | 0.160 |
Why?
|
| Pain Measurement | 5 | 2013 | 953 | 0.160 |
Why?
|
| Fatigue | 4 | 2012 | 1239 | 0.150 |
Why?
|
| Walking | 1 | 2019 | 277 | 0.150 |
Why?
|
| Dyspnea | 1 | 2019 | 416 | 0.140 |
Why?
|
| Nootropic Agents | 2 | 2007 | 33 | 0.140 |
Why?
|
| Indans | 2 | 2007 | 68 | 0.130 |
Why?
|
| Methylphenidate | 2 | 2006 | 103 | 0.120 |
Why?
|
| Medication Adherence | 1 | 2018 | 492 | 0.110 |
Why?
|
| Paresthesia | 1 | 2013 | 33 | 0.110 |
Why?
|
| Central Nervous System Stimulants | 2 | 2006 | 225 | 0.110 |
Why?
|
| Pilot Projects | 6 | 2019 | 2803 | 0.110 |
Why?
|
| Acupuncture Therapy | 1 | 2013 | 89 | 0.110 |
Why?
|
| Middle Aged | 20 | 2019 | 86204 | 0.110 |
Why?
|
| Injections, Spinal | 1 | 2013 | 257 | 0.110 |
Why?
|
| Humans | 26 | 2024 | 261506 | 0.100 |
Why?
|
| Muscle Weakness | 1 | 2013 | 116 | 0.100 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2012 | 113 | 0.100 |
Why?
|
| Bone Marrow | 1 | 2019 | 2358 | 0.100 |
Why?
|
| Survivors | 1 | 2017 | 1031 | 0.100 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2013 | 191 | 0.090 |
Why?
|
| Piperidines | 2 | 2007 | 1035 | 0.090 |
Why?
|
| Paclitaxel | 2 | 2017 | 1996 | 0.090 |
Why?
|
| Models, Educational | 1 | 2010 | 95 | 0.090 |
Why?
|
| Adult | 14 | 2019 | 77950 | 0.090 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 213 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2011 | 362 | 0.090 |
Why?
|
| Inhibitory Postsynaptic Potentials | 1 | 2008 | 48 | 0.080 |
Why?
|
| Receptors, Muscarinic | 1 | 2008 | 69 | 0.080 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 14289 | 0.080 |
Why?
|
| Vincristine | 1 | 2012 | 1511 | 0.080 |
Why?
|
| Female | 20 | 2019 | 141928 | 0.080 |
Why?
|
| Drug and Narcotic Control | 2 | 2019 | 31 | 0.080 |
Why?
|
| Pyrazines | 1 | 2011 | 495 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 852 | 0.080 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 918 | 0.080 |
Why?
|
| Male | 20 | 2019 | 123000 | 0.080 |
Why?
|
| Curriculum | 1 | 2013 | 860 | 0.070 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2008 | 269 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 2010 | 390 | 0.070 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2013 | 882 | 0.070 |
Why?
|
| Aged | 12 | 2019 | 70117 | 0.060 |
Why?
|
| Spinal Cord | 1 | 2008 | 690 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2010 | 795 | 0.060 |
Why?
|
| Sleep Stages | 1 | 2003 | 78 | 0.060 |
Why?
|
| Narcotics | 1 | 2004 | 123 | 0.060 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 29902 | 0.060 |
Why?
|
| Smoking | 1 | 2012 | 2440 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2019 | 2588 | 0.050 |
Why?
|
| Cost of Illness | 2 | 2018 | 498 | 0.050 |
Why?
|
| Treatment Outcome | 7 | 2018 | 32848 | 0.050 |
Why?
|
| Texas | 3 | 2019 | 6311 | 0.050 |
Why?
|
| Outpatients | 1 | 2004 | 462 | 0.050 |
Why?
|
| Catheters | 1 | 2021 | 126 | 0.050 |
Why?
|
| Death | 1 | 2021 | 119 | 0.050 |
Why?
|
| Surveys and Questionnaires | 4 | 2016 | 5687 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2013 | 2576 | 0.050 |
Why?
|
| Algorithms | 1 | 2011 | 3890 | 0.040 |
Why?
|
| Oral Sprays | 1 | 2019 | 8 | 0.040 |
Why?
|
| Administration, Sublingual | 1 | 2019 | 25 | 0.040 |
Why?
|
| Walk Test | 1 | 2019 | 43 | 0.040 |
Why?
|
| Physicians | 2 | 2019 | 882 | 0.040 |
Why?
|
| Physical Exertion | 1 | 2019 | 113 | 0.040 |
Why?
|
| Pain Clinics | 1 | 2018 | 17 | 0.040 |
Why?
|
| Palliative Care | 1 | 2010 | 2037 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 4314 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 430 | 0.040 |
Why?
|
| Neurons | 1 | 2008 | 2287 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 621 | 0.040 |
Why?
|
| United States Government Agencies | 1 | 2016 | 9 | 0.040 |
Why?
|
| Platinum Compounds | 1 | 2017 | 131 | 0.040 |
Why?
|
| Psychological Theory | 1 | 2016 | 47 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2019 | 9244 | 0.030 |
Why?
|
| Intention | 1 | 2016 | 109 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2021 | 37905 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2016 | 170 | 0.030 |
Why?
|
| Self Administration | 2 | 2006 | 50 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2017 | 263 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1363 | 0.030 |
Why?
|
| Young Adult | 3 | 2019 | 21445 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 756 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 702 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1945 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2018 | 898 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 967 | 0.030 |
Why?
|
| Thermosensing | 1 | 2012 | 9 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2021 | 12873 | 0.030 |
Why?
|
| Mechanoreceptors | 1 | 2012 | 28 | 0.030 |
Why?
|
| Sensory Thresholds | 1 | 2012 | 68 | 0.030 |
Why?
|
| Physical Stimulation | 1 | 2012 | 112 | 0.030 |
Why?
|
| Crime | 1 | 2012 | 31 | 0.030 |
Why?
|
| Touch | 1 | 2012 | 71 | 0.030 |
Why?
|
| Appetite | 1 | 2012 | 73 | 0.030 |
Why?
|
| Nerve Fibers | 1 | 2012 | 106 | 0.030 |
Why?
|
| Motor Skills | 1 | 2012 | 107 | 0.030 |
Why?
|
| Empathy | 1 | 2013 | 101 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 600 | 0.030 |
Why?
|
| Mood Disorders | 1 | 2012 | 163 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 4938 | 0.020 |
Why?
|
| Cancer Survivors | 1 | 2018 | 650 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2008 | 11965 | 0.020 |
Why?
|
| Genital Neoplasms, Female | 1 | 2017 | 735 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 482 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 14889 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2013 | 6869 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 1085 | 0.020 |
Why?
|
| Bortezomib | 1 | 2011 | 543 | 0.020 |
Why?
|
| Oxotremorine | 1 | 2008 | 24 | 0.020 |
Why?
|
| Anthracenes | 1 | 2008 | 48 | 0.020 |
Why?
|
| Muscarinic Agonists | 1 | 2008 | 40 | 0.020 |
Why?
|
| Nickel | 1 | 2008 | 44 | 0.020 |
Why?
|
| Cadmium | 1 | 2008 | 57 | 0.020 |
Why?
|
| Time Factors | 2 | 2017 | 12926 | 0.020 |
Why?
|
| Biophysics | 1 | 2008 | 111 | 0.020 |
Why?
|
| Potassium Channel Blockers | 1 | 2008 | 110 | 0.020 |
Why?
|
| Teaching | 1 | 2010 | 243 | 0.020 |
Why?
|
| Ion Channel Gating | 1 | 2008 | 141 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 2008 | 147 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2008 | 388 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2008 | 426 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2008 | 553 | 0.020 |
Why?
|
| Skin | 1 | 2012 | 1259 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 2352 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 437 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2008 | 1618 | 0.020 |
Why?
|
| Risk Factors | 2 | 2013 | 17523 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 3443 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2013 | 1270 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 4113 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 2063 | 0.010 |
Why?
|
| Quality of Life | 1 | 2018 | 4532 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 216 | 0.010 |
Why?
|
| Incidence | 1 | 2013 | 5673 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 2216 | 0.010 |
Why?
|
| Calcium | 1 | 2008 | 1537 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 1879 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2004 | 1544 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 6086 | 0.010 |
Why?
|
| United States | 1 | 2016 | 15433 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 6150 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 4053 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 6682 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 15694 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 59536 | 0.000 |
Why?
|